

Mumps IgG Capture EIA

BluePoint Bioscience is proud to announce a distribution agreement with Microimmune, Limited. U.K. Microimmune is a leading manufacturer of kits for the serological diagnosis and surveillance of vaccine-preventable diseases. Microimmune produces kits for in-vitro diagnostic use in the detection of IgG and IgM antibodies to mumps and measles virus in human serum and plasma.

Test Principle

In the Mumps IgG capture EIA, diluted serum/plasma is added to anti-human IgG coated microtitre wells. IgG in the specimen binds to the wells and, after washing, recombinant mumps nucleoprotein (rMuNP) antigen is added. Mumps specific IgG in the sample, if present, binds the rMuNP. After washing the wells, a monoclonal antibody to the rMuNP, conjugated to horseradish peroxidase is added to reveal the presence of mumps specific IgG. After washing, tetramethylbenzidine (TMB) substrate is added. The presence of mumps specific IgG in the sample results in a color change in the TMB from colorless to blue. The enzymatic reaction is terminated with acid, which causes further color change from blue to yellow. The color change and intensity are monitored using a spectrophotometric plate reader. The presence of mumps specific IgG is indicated by optical density values above the cut-off.

Kit Features

- * Specimen type: serum/plasma
- * Reagents: Color coded and mostly ready to use
- * No sample pretreatment other than dilution
- * Shelf life: 12 months at 2-8 degrees Celsius
- * Sensitivity of the Mumps IgG capture EIA on serum samples compared to two competitor tests was 100% (95% CI 95.7% to 100.0%) for test 1 and 94.3% (95% CI 88.1% to 97.7%) for test 2
- * Specificity of Mumps IgG capture EIA on serum samples compared competitor test 1: 94.2% (95% CI 84.1 to 98.9)

To order contact BluePoint Bioscience
Catalog # MuVG012

